News | November 09, 2011

Medtronic Presents Results of Resolute DES Clinical Trials at TCT 2011

November 9, 2011 — Currently under review by the U.S. Food and Drug Administration (FDA), the Resolute drug-eluting stent (DES) from Medtronic Inc. continues to demonstrate consistently positive performance across a variety of studies. These conclusions come from two new data analyses being presented this week at Transcatheter Cardiovascular Therapeutics (TCT) 2011.

The first analysis, RESOLUTE Pooled Diabetics, focuses on outcomes in patients with both coronary artery disease (CAD) and diabetes; the second, RESOLUTE Pooled Safety, focuses on safety outcomes across all patient types.

More than 1,500 patients with diabetes mellitus participated in the global clinical program to evaluate Resolute’s performance in the treatment of CAD. The implantable medical device showed strong results through one year of follow-up. 

Prof. Sigmund Silber, M.D., FACC, FESC, director of the Heart Centre at the Isar in Munich, Germany, will present the results of this analysis at TCT. The event is the Cardiovascular Research Foundation’s annual scientific symposium for interventional cardiovascular specialists.

“People with diabetes and heart disease constitute about one-third of the patients that receive percutaneous coronary interventions worldwide,” explained Silber. “They are an especially challenging group of patients to treat because of their increased risk of subsequent cardiovascular events, including heart attack and cardiac death, as well as repeat procedures in the target vessel.”

RESOLUTE Pooled Diabetics

This post-hoc pooled analysis of the Resolute clinical program presents the outcomes of all 1,535 diabetes patients treated with a Resolute DES in five studies to those without diabetes. For contemporary context, it compares these outcomes to those of patients who received a Xience V DES from Abbott Laboratories in the randomized RESOLUTE All Comers trial. 

The analysis also presents the outcomes in insulin-dependent and non-insulin-dependent as well as patients without diabetes treated with a Resolute DES.

The study shows very similar and low rates of events across these patient subsets. No differences were observed between the Resolute and Xience arms after propensity adjustment. The RESLOUTE Pooled Diabetics analysis will be presented at the session titled “Intersection of Diabetes and PCI.”

“This pooled data analysis found low event rates for the Resolute DES through one-year of follow-up among patients with or without diabetes, and even among patients with insulin-dependent diabetes, although we need more data in this special subgroup,” Silber concluded.

RESOLUTE Pooled Safety

Following Silber’s presentation, Martin Leon, M.D., of New York-Presbyterian Hospital/Columbia University Medical Center will present two-year safety data from the global Resolute clinical program; more than 5,000 patients treated with the Resolute DES were enrolled. His presentation will occur during the session titled “Predictors and Prevention of Stent Thrombosis.”

The results of this post-hoc analysis, termed RESOLUTE Pooled Safety, were compared to those patients who received a Xience V DES in the RESOLUTE All Comers trial. No differences were observed between the Resolute and Xience arms after propensity adjustment.

RESOLUTE (First-in-Human Study)

Also presented at TCT 2011 will be the final, five-year follow-up from the original feasibility study of the Resolute DES. The results include zero ARC def/prob ST and a target lesion revascularization (TLR) rate of 3.1 percent in 130 patients. Prof. Ian Meredith of Monash Medical Centre in Melbourne, Australia will make this presentation on Tuesday during the session titled “Drug-Eluting Stents II.”

The Resolute DES is commercially available in more than 100 countries outside the United States; where its use is limited by U.S. law to clinical trials approved by the FDA. Medtronic continues to anticipate FDA approval of the device in the first half of 2012.

The clinical program will ultimately enroll more than 6,000 patients worldwide and involves a collaborative effort involving hundreds of medical centers in more than 25 countries.

For more information: www.medtronic.com

Related Content

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Overlay Init